Antonino Cassotta

Antonino Cassotta

Biträdande Lektor
Besöksadress: Blickagången 16, 14152 Huddinge
Postadress: H7 Medicin, Huddinge, H7 HERM Bryceson Cassotta, 171 77 Stockholm
Del av:

Om mig

  • Mitt forskningslaboratorium syftar till att dissekera den mänskliga T-cellsrepertoaren som riktar sig mot tumör- och självantigener på klonal nivå. Genom denna metod strävar vi efter att avslöja reglerna som styr immundominans, klonal selektion och immuntolerans i olika mänskliga sjukdomskontexter.
    Genom att lära av naturen strävar vi efter att identifiera terapeutiskt relevanta T-cellsreceptorer och epitoper och utnyttja dem för att utveckla nästa generations immunterapier.

Utvalda publikationer

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Swedish Research Council
    1 January 2026 - 31 December 2029
    Multiple myeloma (MM) is a malignancy of plasma cells that produce a uniquely rearranged monoclonal antibody, known as M-protein. The failure of the immune system to eliminate malignant plasma cells remains incompletely understood. Despite therapeutic advancements, MM remains incurable due to recurrent relapses, highlighting the urgent need for new treatment strategies. Genome editing technologies enable the development of cell-based immunotherapies with enhanced specificity and efficacy. Here, I will investigate the endogenous T cell response to MM by characterizing the specificity and function of tumor-reactive T cells within the bone marrow microenvironment. In parallel, I will identify T cell receptors (TCRs) targeting tumor antigens, including conserved idiotypic epitopes from M-proteins and recurrently mutated oncogenes, to develop novel TCR-based immunotherapies. Using precise genome editing, I will engineer TCR-transgenic T cells and natural killer (NK) cells to mitigate tumor evasion due to MHC loss. By dissecting the TCR repertoire and specificity of the endogenous T cell response in MM, this study will provide key insights into immune evasion mechanisms and enable new off-the-shelf and multiplexed TCR-based immunotherapies. The knowledge and methodologies generated in this study will not only advance treatment strategies for MM but also inform the design of next-generation precision immunotherapies against other malignancies.
  • Swiss National Science Foundation
    1 March 2024 - 28 February 2025
  • Dynamics of immune response after myocardial infarction and its role in the pathogenesis of heart failure
    Swiss Heart Foundation
    1 January 2024 - 1 January 2025
  • Cardiac-specific regulatory and conventional CD4+ T cells in healthy donors and myocardial infarction patients
    Novartis Foundation for Medical-Biological Research
    1 January 2023 - 1 January 2024

Anställningar

  • Biträdande Lektor, Medicin, Huddinge, Karolinska Institutet, 2026-2031
  • Research associate, A semi-independent position that allowed me to hire personnel and run independent research, Institute for Research in Biomedicine, 2024-2025
  • Postdoctoral researcher, Federica Sallusto laboratory, Institute for Research in Biomedicine, 2020-2023
  • Visiting scientist, Antonio Lanzavecchia laboratory, Istituto Nazionale Genetica Molecolare, 2020-2022
  • PhD student, Federica Sallusto laboratory, Institute for Research in Biomedicine, 2014-2020
  • Research internship (volunteer), Rosa Sorrentino laboratory, Sapienza University of Rome, 2008-2013

Examina och utbildning

  • PhD, Human immunology, Clonal selection and immunodominance in the human T cell response to microbial antigens and biologicals, ETH Zurich, 2020
  • Master’s degree, Medical Biotechnology, Study of myeloid cells differentiation: modulation of molecules involved in classical and non-classical pathways of antigen presentation, Sapienza University of Rome, 2013
  • Bachelor degree, Biotechnology, Study of genetic association between ERAP1 gene and Ankylosing Spondylitis in Sardinia, Sapienza University of Rome, 2011

Nyheter från KI

Kalenderhändelser från KI